IP Library Patent Application 12209961
Patent Application
App. No. 12/209,961

TRANSDERMAL HORMONE SPRAY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/209,961
Abstract

The present invention provides a transdermal spray drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention.

Claims (28)

1 . A transdermal estrogen spray composition, comprising:

a therapeutically effective amount of an estrogen;

a penetration enhancer; and

a volatile solvent,

wherein the penetration enhancer is selected from terpenes, terpenoids, essential oils, pyrrolidones, azones, sulfoxides, amides, alcohols, glycols, glycerides, amino acid derivatives, phospholipids, surfactants, and fatty acids and esters thereof having the formula I a or I b :

R 1 —C(═O)—O—H  I a

or

R 2 —C(═O)—O—R 3   I b

wherein:

R 1 is selected from a straight chain, branched, or cyclic-containing alkyl group or substituted alkyl group having 8 to 20 carbons, and a straight chain, branched, or cyclic-containing alkenyl group or substituted alkenyl group having 8 to 20 carbons;

R 2 is selected from a straight chain, branched, or cyclic-containing alkyl group or substituted alkyl group having 8 to 20 carbons, and a straight chain, branched, or cyclic-containing alkenyl group or substituted alkenyl group having 8 to 20 carbons; and

R 3 is selected from lower alkyl, lower alkenyl, a straight chain, branched, or cyclic-containing alkyl group or substituted alkyl group having 6 to 14 carbons, and a straight chain, branched, or cyclic-containing alkenyl group or substituted alkenyl group having 6 to 14 carbons; and

the substituted alkyls or substituted alkenyls have from 1 to 4 substituents selected from hydroxy, halo, oxo, alkoxy, and amino; and

wherein, when applied to the skin, the composition provides an in vivo transdermal flux of estrogen of about 0.03 to about 0.3 μg/cm 2 per hour.

2 . The transdermal estrogen spray of claim 1 , wherein the estrogen is estradiol.

3 . The transdermal estrogen spray of claim 1 , wherein the penetration enhancer is selected from the groups consisting of terpenes, terpenoids, essential oils, pyrrolidones, azones, fatty acids, fatty acid esters, sulfoxides, amides, alcohols, glycols and glycerides, amino acid derivatives, phospholipids, and surfactants.

4 . The transdermal estrogen spray of claim 3 , wherein the penetration enhancer is a fatty acid or a fatty acid ester.

5 . The transdermal estrogen spray of claim 4 , wherein the penetration enhancer is selected from a compound having the formula I a or I b :

R 1 —C(═O)—O—H  I a

or

R 2 —C(═O)—O—R 3   I b

wherein:

R 1 is selected from a straight chain, branched, or cyclic-containing alkyl group or substituted alkyl group having 8 to 20 carbons, and a straight chain, branched, or cyclic-containing alkenyl group or substituted alkenyl group having 8 to 20 carbons;

R 2 is selected from a straight chain, branched, or cyclic-containing alkyl group or substituted alkyl group having 8 to 20 carbons, and a straight chain, branched, or cyclic-containing alkenyl group or substituted alkenyl group having 8 to 20 carbons; and

R 3 is selected from lower alkyl, lower alkenyl, a straight chain, branched, or cyclic-containing alkyl group or substituted alkyl group having 6 to 14 carbons, and a straight chain, branched, or cyclic-containing alkenyl group or substituted alkenyl group having 6 to 14 carbons; and

the substituted alkyls or substituted alkenyls have from 1 to 4 substituents selected from hydroxy, halo, oxo, alkoxy, and amino.

6 . The transdermal estrogen spray of claim 3 , wherein the penetration enhancer is selected from the group consisting of butylated hydroxyanisole, 2-phenoxyethanol, thymol, menthol, menthone, cineole, isopropyl myristate, glyceryl monolaurate, glyceryl monostearate, glyceryl monooleate, oleic acid, oleyl alcohol, methyl laurate, sorbitan monooleate, lauryl lactate, and lauryl alcohol.

7 . The transdermal estrogen spray of claim 1 , wherein the solvent is selected from ethanol and isopropanol.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2011
From: U.S. HEALTHCARE, LLC (AS ADMINISTRATIVE AND COLLATERAL AGENT)
To: DRUGTECH CORPORATION
Reel/Frame 025980/0024 →
SECURITY AGREEMENT Recorded Mar 18, 2011
From: DRUGTECH CORPORATION
To: WILMINGTON TRUST FSB (AS COLLATERAL AGENT)
Reel/Frame 025981/0068 →
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2011
From: U.S. HEALTHCARE I, LLC (AS ADMINISTRATIVE AND COLLATERAL AGENT)
To: DRUGTECH CORPORATION
Reel/Frame 025981/0934 →
PATENT SECURITY AGREEMENT Recorded Nov 20, 2010
From: DRUGTECH CORPORATION
To: U.S. HEALTHCARE I, LLC
Reel/Frame 025385/0498 →
PATENT SECURITY AGREEMENT Recorded Sep 14, 2010
From: DRUGTECH CORPORATION
To: U.S. HEALTHCARE I, L.L.C.
Reel/Frame 024982/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2008
From: LEVINSON, R. SAUL; MILLER, LARRY G
To: DRUGTECH CORPORATION
Reel/Frame 021883/0776 →